Annexon
CompanyUnited StatesROR
Annexon develops one asset, in phase 3 (vonaprument in geographic atrophy). Mostly antibody acting on inflammation, C1QA and C1Q; based in the United States.
- Assets
- 1
- Furthest
- Phase 3
- Trials
- 1
- Signals
- 0
Pipeline
1Inhibits classical complement pathway component C1q to protect synapses
Phase 3AntibodyInflammationC1QAgeographic atrophy
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials1
- Similar companies6
Updated 7 Oct 2026 · 2 sources